Highlighting its continued focus in oncology, GlaxoSmithKline (GSK) has agreed to partner with IDEAYA Biosciences for its synthetic lethality programmes targeting MAT2A, Pol Theta, and Werner Helicase. The deal, which is worth up US$3 B, gives GSK access to programmes that complement its own PARP inhibitor, Zejula® (niraparib), as well as two of its early-stage PRMT inhibitors: GSK3368715 and GSK3326595; the partnership will also look at combination therapies.